The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
Abstract
Prolonged perioperative delivery of immunotherapy prevents local tumor recurrence and eliminates established spontaneous metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Genes that mediate breast cancer metastasis to lung
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005) · Nature · doi:10.1038/nature03799 · Cited by 2,922
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“A given drug can exhibit differential efficacy depending on the degree of tumor progression at which the drug is administered (36).”
BackgroundHyaluronic Acid Hydrogels for Biomedical Applications
Burdick, J. A., & Prestwich, G. D. (2011) · Advanced Materials · doi:10.1002/adma.201003963 · Cited by 2,139
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
Metastasis: a question of life or death
Mehlen, P., & Puisieux, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1886 · Cited by 1,863
Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 5×
“R848 is a Toll-like receptor 7/8 (TLR7/8) agonist that induces expression of type I IFNs and costimulatory molecules by plasmacytoid dendritic cells as well as phenotypic maturation of conventional dendritic cells (27).”
BackgroundInfluentialChang, H. Y., Nuyten, D. S. A., Sneddon, J. B., Hastie, T., Tibshirani, R., Sørlie, T., Dai, H., He, Y. D., van't Veer, L. J., Bartelink, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409462102 · Cited by 981
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Early dissemination seeds metastasis in breast cancer
Hosseini, H., Obradović, M. M. S., Hoffmann, M., Harper, K. L., Sosa, M. S., Werner-Klein, M., Nanduri, L. K., Werno, C., Ehrl, C., Maneck, M., et al. (2016) · Nature · doi:10.1038/nature20785 · Cited by 740
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.025 · Cited by 649
Mechanism of early dissemination and metastasis in Her2+ mammary cancer
Harper, K. L., Sosa, M. S., Entenberg, D., Hosseini, H., Cheung, J. F., Nobre, R., Avivar-Valderas, A., Nagi, C., Girnius, N., Davis, R. J., et al. (2016) · Nature · doi:10.1038/nature20609 · Cited by 562
Kim, J., Li, W. A., Choi, Y., Lewin, S. A., Verbeke, C. S., Dranoff, G., & Mooney, D. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3071 · Cited by 541
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
Gajewski, T. F. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.011 · Cited by 488
Exploiting the critical perioperative period to improve long-term cancer outcomes
Horowitz, M., Neeman, E., Sharon, E., & Ben-Eliyahu, S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.224 · Cited by 487
Acquired resistance to immunotherapy and future challenges
Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.2 · Cited by 467
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
Sagiv-Barfi, I., Kohrt, H. E. K., Czerwinski, D. K., Ng, P. P., Chang, B. Y., & Levy, R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500712112 · Cited by 444
Biopolymer implants enhance the efficacy of adoptive T-cell therapy
Stephan, S. B., Taber, A. M., Jileaeva, I., Pegues, E. P., Sentman, C. L., & Stephan, M. T. (2015) · Nature Biotechnology · doi:10.1038/nbt.3104 · Cited by 439
Converting IL-15 to a superagonist by binding to soluble IL-15Rα
Rubinstein, M. P., Kovar, M., Purton, J. F., Cho, J.-H., Boyman, O., Surh, C. D., & Sprent, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600240103 · Cited by 416
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 386
Hydrogels and Scaffolds for Immunomodulation
Singh, A., & Peppas, N. A. (2014) · Advanced Materials · doi:10.1002/adma.201402105 · Cited by 355
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Smith, T. T., Moffett, H. F., Stephan, S. B., Opel, C. F., Dumigan, A. G., Jiang, X., Pillarisetty, V. G., Pillai, S. P. S., Wittrup, K. D., & Stephan, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87624 · Cited by 336
Local Therapy and Survival in Breast Cancer
Punglia, R. S., Morrow, M., Winer, E. P., & Harris, J. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmra065241 · Cited by 317
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 307
Loré, K., Betts, M. R., Brenchley, J. M., Kuruppu, J., Khojasteh, S., Perfetto, S., Roederer, M., Seder, R. A., & Koup, R. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4320 · Cited by 291
Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
Goldberg, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.037 · Cited by 278
Self-citationIn Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice
Ali, O. A., Emerich, D., Dranoff, G., & Mooney, D. J. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000359 · Cited by 246
Tai, L.-H., de Souza, C. T., Bélanger, S., Ly, L., Alkayyal, A. A., Zhang, J., Rintoul, J. L., Ananth, A. A., Lam, T., Breitbach, C. J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1993 · Cited by 241
Rook, A. H., Gelfand, J. M., Wysocka, M., Troxel, A. B., Benoit, B., Surber, C., Elenitsas, R., Buchanan, M. A., Leahy, D. S., Watanabe, R., et al. (2015) · Blood · doi:10.1182/blood-2015-02-630335 · Cited by 224
Intratumoral Immunization: A New Paradigm for Cancer Therapy
Marabelle, A., Kohrt, H., Caux, C., & Levy, R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2116 · Cited by 214
Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity
Li, Y., Fang, M., Zhang, J., Wang, J., Song, Y., Shi, J., Li, W., Wu, G., Ren, J., Wang, Z., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1074374 · Cited by 203
Predicting a local recurrence after breast-conserving therapy by gene expression profiling
Nuyten, D. S., Kreike, B., Hart, A. A., Chi, J.-T. A., Sneddon, J. B., Wessels, L. F., Peterse, H. J., Bartelink, H., Brown, P. O., Chang, H. Y., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1614 · Cited by 202
Kwong, B., Gai, S. A., Elkhader, J., Wittrup, K. D., & Irvine, D. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3343 · Cited by 197
MacFarlane, A. W., Jillab, M., Plimack, E. R., Hudes, G. R., Uzzo, R. G., Litwin, S., Dulaimi, E., Al-Saleem, T., & Campbell, K. S. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0133 · Cited by 177
Kwong, B., Liu, H., & Irvine, D. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.067 · Cited by 175
Kim, P. S., Kwilas, A. R., Xu, W. V., Alter, S., Jeng, E. K., Wong, H. C., Schlom, J., & Hodge, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.7470 · Cited by 166
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events
Ishihara, J., Fukunaga, K., Ishihara, A., Larsson, H. M., Potin, L., Hosseinchi, P., Galliverti, G., Swartz, M. A., & Hubbell, J. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0401 · Cited by 162
Devaud, C., Westwood, J. A., John, L. B., Flynn, J. K., Paquet‐Fifield, S., Duong, C. P. M., Yong, C. S. M., Pegram, H. J., Stacker, S. A., Achen, M. G., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.219 · Cited by 131
Retsky, M. W., Demicheli, R., Hrushesky, W. J. M., Forget, P., Kock, M. D., Gukas, I. D., Rogers, R. A., Baum, M., Sukhatme, V. P., & Vaidya, J. S. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990250 · Cited by 121
Neeman, E., Zmora, O., & Ben‐Eliyahu, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1087 · Cited by 118
Surgical Injury Enhances the Expression of Genes That Mediate Breast Cancer Metastasis to the Lung
Al-Sahaf, O., Wang, J. H., Browne, T. J., Cotter, T. G., & Redmond, H. P. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181efc635 · Cited by 97
Spel, L., Boelens, J. J., Nierkens, S., & Boes, M. L. (2013) · OncoImmunology · doi:10.4161/onci.26403 · Cited by 77
Hofland, K. F., Thougaard, A., Sehested, M., & Jensen, P. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2343 · Cited by 46
Tai, L., de Souza, C. T., Sahi, S., Zhang, J., Alkayyal, A. A., Ananth, A. A., & Auer, R. C. (2014) · Journal of Visualized Experiments · doi:10.3791/51253 · Cited by 40
Tai, L., de Souza, C. T., Sahi, S., Zhang, J., Alkayyal, A. A., Ananth, A. A., & Auer, R. C. (2014) · Journal of Visualized Experiments · doi:10.3791/51253-v · Cited by 11
Recapitulating human cancer in a mouse
Chin, L., de Sauvage, F. J., Egeblad, M., Olive, K. P., Tuveson, D. A., & Weiss, W. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2575 · Cited by 6
Cited by
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Chen, Q., Wang, C., Zhang, X., Chen, G., Hu, Q., Li, H., Wang, J., Wen, D., Zhang, Y., Lu, Y., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0319-4 · Cited by 1,010
Improving cancer immunotherapy through nanotechnology
Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628
Self-citationRoles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
Activating an adaptive immune response from a hydrogel scaffold imparts regenerative wound healing
Griffin, D. R., Archang, M. M., Kuan, C.-H., Weaver, W. M., Weinstein, J. S., Feng, A. C., Ruccia, A., Sideris, E., Ragkousis, V., Koh, J., et al. (2021) · Nature Materials · doi:10.1038/s41563-020-00844-w · Cited by 505
Xing, C., Chen, S., Liang, X., Liu, Q., Qu, M., Zou, Q., Li, J., Tan, H., Liu, L., Fan, D., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b08314 · Cited by 488
Metadata
- Authors
- Park, C. G., Hartl, C. A., Schmid, D., Carmona, E. M., Kim, H.-J., & Goldberg, M. S.
- Venue
- Science Translational Medicine
- Published
- 2018-03-21
- Volume
- 10
- Issue
- 433
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2791931250
- Cited by
- 321
- References
- 54
- FWCI
- 11.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.